National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden.
Sex Transm Infect. 2010 Nov;86(6):454-60. doi: 10.1136/sti.2010.045377.
Neisseria gonorrhoeae has developed resistance to most antimicrobials used for treatment. Worryingly, treatment failures with oral extended-spectrum cephalosporins (ESCs) have been reported, especially in the WHO Western Pacific Region, and susceptibility to all ESCs (oral and injectable), the last remaining treatment options in many settings, is decreasing globally.
To examine the emergence, spread and characteristics of Neisseria gonorrhoeae isolates with decreased susceptibility and resistance to ESCs in Sweden.
All available Swedish isolates from 1998-2009, collected from many countries worldwide, displaying decreased susceptibility to cefixime and/or ceftriaxone (minimum inhibitory concentration (MIC) ≥ 0.032 mg/l; n=331) were examined using antibiograms, full-length porB gene sequencing, N gonorrhoeae multi-antigen sequence typing (NG-MAST), and sequencing of ESC resistance determinants (penA, mtrR and porB1b (penB alteration)).
Based on EUCAST breakpoints, 30 (9.1%) and one (0.3%) of the isolates displayed in vitro resistance to cefixime and ceftriaxone, respectively. penA mosaic alleles and penA A501 alteration were detected in 24% and 11%, respectively, of the isolates, and in increasing prevalence over the years. Moreover, among these isolates 38 NG-MAST sequence type (STs) were detected, with ST1407 (n=29), ST1103 (n=9) and ST3378 (n=8) being most common.
The proportions of N gonorrhoeae isolates with decreased susceptibility and resistance to ESCs have substantially increased over the years in Sweden. Both penA mosaic alleles and the penA A501 alteration, together with mtrR and penB, are important for the decreased susceptibility and resistance to ESCs. At least one gonococcal penA mosaic strain (ST1407), including its evolving subtypes, with decreased susceptibility/resistance to ESCs circulates worldwide.
淋病奈瑟菌已对大多数用于治疗的抗菌药物产生耐药性。令人担忧的是,口服扩展谱头孢菌素(ESC)治疗失败的情况已被报道,尤其是在世界卫生组织西太平洋区域,而在许多情况下,作为最后治疗选择的所有 ESC(口服和注射)的敏感性正在全球范围内下降。
研究瑞典对 ESC 敏感性降低和耐药的淋病奈瑟菌分离株的出现、传播和特征。
对 1998 年至 2009 年从全球许多国家收集的、对头孢克肟和/或头孢曲松(最低抑菌浓度(MIC)≥0.032mg/L;n=331)敏感性降低的所有瑞典可用分离株进行了研究,使用抗生素谱、全长 porB 基因测序、淋病奈瑟菌多抗原序列分型(NG-MAST)以及 ESC 耐药决定因素(penA、mtrR 和 porB1b(penB 改变))测序。
根据 EUCAST 折点,30 株(9.1%)和 1 株(0.3%)分离株对头孢克肟和头孢曲松分别显示体外耐药。24%和 11%的分离株分别检测到 penA 马赛克等位基因和 penA A501 改变,且这些等位基因的出现频率逐年增加。此外,在这些分离株中检测到 38 种 NG-MAST 序列型(ST),其中 ST1407(n=29)、ST1103(n=9)和 ST3378(n=8)最为常见。
近年来,瑞典对 ESC 敏感性降低和耐药的淋病奈瑟菌分离株的比例大幅增加。penA 马赛克等位基因和 penA A501 改变以及 mtrR 和 penB 对 ESC 的敏感性降低和耐药性均很重要。至少有一种淋病奈瑟菌 penA 马赛克株(ST1407),包括其不断进化的亚型,对 ESC 的敏感性/耐药性降低,在全球范围内传播。